NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: NASDAQ:SLS), a biopharmaceutical company engaged in developing cancer therapies, has released preliminary data from its Phase 2a trial of SLS009, a drug targeting acute myeloid leukemia (AML) with specific genetic mutations. The study focuses on the ASXL1 mutation prevalent in myeloid malignancies and solid tumors, which is often linked to poor patient outcomes.
The trial achieved a 57% overall response rate in the selected 30 mg BIW (bi-weekly) dose cohort, surpassing the targeted 20% rate. Remarkably, all AML patients with ASXL1 truncating mutations at this dosage level have responded to the treatment and remain alive. The company has expanded the trial to include cohorts with ASXL1 mutations and other myelodysplasia-related molecular abnormalities.
SELLAS has successfully filed a provisional patent application related to the ASXL1 mutation and SLS009, which includes all CDK9 inhibitor drugs. The ASXL1 mutation is associated with a reduced response to current treatments, making this development significant for patients with AML and potentially other cancers with similar biological profiles.
The company's CEO, Angelos Stergiou, MD, expressed optimism about SLS009's potential to address unmet medical needs in AML and other tumor types harboring the ASXL1 mutation. SELLAS is considering initiating discussions with the U.S. Food and Drug Administration (FDA) regarding an accelerated approval pathway for SLS009 in this molecularly defined AML patient population.
The ongoing Phase 2a clinical trial is an open-label, single-arm, multi-center study designed to assess the safety, tolerability, and efficacy of SLS009 in combination with standard treatments. Enrollment continues for the expansion cohort receiving the 30 mg BIW dose with the ASXL1 mutation. Further updates on the trial are expected in Q3 2024.
The ASXL1 mutation is found in a significant portion of patients with hematologic malignancies and solid tumors, indicating a substantial market potential for SLS009 if it continues to demonstrate efficacy. This press release statement provides a factual basis for the reported developments.
InvestingPro Insights
As SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) makes headway with its promising clinical trial results for SLS009, the market's response to the company's progress is a vital aspect for investors to consider. According to real-time data from InvestingPro, SELLAS carries a market capitalization of $69.77 million. Despite the company's innovative strides in addressing acute myeloid leukemia (AML), the financial metrics suggest caution, with a negative price-to-earnings (P/E) ratio of -0.91, reflecting the company's current lack of profitability.
Investors should note that the company's stock has been characterized by high volatility, as evidenced by a 19.48% drop in the one-week price total return, yet an impressive 107.53% surge over the last three months. This volatility is an important consideration for those looking to invest in the biopharmaceutical sector, where clinical trial outcomes can significantly impact stock prices. Additionally, SELLAS does not pay a dividend to shareholders, which can be a deciding factor for income-focused investors.
Two key InvestingPro Tips for SELLAS suggest that the company suffers from weak gross profit margins and that analysts do not anticipate profitability this year. These insights could be particularly relevant for investors weighing the potential risks and rewards of investing in a company that is in the process of developing breakthrough medical treatments. With the next earnings date set for May 9, 2024, stakeholders will be keen to see if the recent clinical successes can start to translate into financial improvements.
For those interested in a deeper dive into SELLAS's financial health and future prospects, InvestingPro offers additional tips and metrics. To enhance your investment strategy with these insights, consider subscribing to InvestingPro, and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With over ten additional InvestingPro Tips available, investors can gain a more nuanced understanding of SELLAS's financial landscape and make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.